IVAX remains 'active'

Related tags Manufacturing

Pharmaceutical and veterinary product manufacturer IVAX corporation
has acquired ChemSource, a manufacturer of active pharmaceutical
ingredients based in Puerto Rico.

Pharmaceutical and veterinary product manufacturer IVAX corporation has acquired ChemSource, a manufacturer of active pharmaceutical ingredients based in Puerto Rico.

Purchased from Chemo Iberica, and Quimica Sintetica, ChemSource develops, manufactures and sells active pharmaceutical ingredients (API) for various pharmaceutical products, including products currently being sold or under development by IVAX.

"This acquisition represents an important expansion of our API manufacturing capabilities and furthers our goal of achieving vertical integration by providing us with additional capacity and expertise to manufacture the active ingredients utilised in pharmaceutical products,"​ said Phillip Frost, chairman and chief executive officer of IVAX.

According to IVAX, the API products manufactured at the acquired facility complement those now manufactured at IVAX' facility in the Czech Republic.

Terms of the agreement were not disclosed.

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars